RFC
GYRE icon

Russell Frank Company’s Gyre Therapeutics GYRE Stock Holding History

Russell Frank Company’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-53
Closed -$223K – 2898
2013
Q3 		$223K Sell
53
-130
-71% -$523K ﹤0.01% 2734
2013
Q2 		$616K Buy
+183
New +$696K ﹤0.01% 2256

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Frank Company's GYRE Position: Q4 2013 in Review

Russell Frank Company sold out of Gyre Therapeutics (GYRE) in Q4 2013, closing a stake of 53 shares — an estimated $223K sold.

Russell Frank Company first reported a position in GYRE in Q2 2013 and held it in 2 quarters. The position peaked at $616K in Q2 2013. 74 funds tracked by Wall St. Rank hold GYRE as of Q4 2013.

  • Russell Frank Company reported no remaining Gyre Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Russell Frank Company sold 53 Gyre Therapeutics shares in Q4 2013, an estimated $223K.
  • Russell Frank Company first reported a position in Gyre Therapeutics in Q2 2013 and held it in 2 quarters.
  • Russell Frank Company's Gyre Therapeutics position peaked at $616K in Q2 2013.
  • 74 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2013.

Based on Russell Frank Company's 13F filing for Q4 2013, filed 14 Feb 2014.